Deferasirox is under clinical development by Austhera BioSciences and currently in Phase II for Thalassemia. According to GlobalData, Phase II drugs for Thalassemia have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Deferasirox’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Deferasirox overview

Deferasirox (DST-0509, KDFX) is under development for the treatment of iron overload in transfusion-dependent major thalassemia (TDT) patients. The drug candidate is formulated as a tablet and administered through oral route. It acts by targeting iron. The drug candidate is developed based on Kinetisol technology.

Austhera BioSciences overview

Austhera BioSciences is a pharmaceutical development company that develops transformative drug candidates and novel chemical entities for the treatment of cancer and rare diseases. Austhera BioSciences is headquartered in Georgetown, Texas, the US.

For a complete picture of Deferasirox’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.